Device Trial Radar · NCT07683572
Device Validation of Augmented-Reality ICG Fluorescence Imaging for Sentinel Lymph Node Detection in Breast Cancer
Last checked: Nov 19, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Withdrawn
Enrollment
0
Actual
Start
Jul 1, 2026
Primary completion
Jul 1, 2028
Study completion Dec 31, 2028
Sponsor
- Lead sponsor
- Ss. Cyril and Methodius University of SkopjeAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- University of Illinois at Urbana-Champaign
- First posted
- Jul 6, 2026
Design
- Study type
- Observational
- FDA-regulated device
- No
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study evaluates how accurately augmented-reality goggles with indocyanine green (ICG) near-infrared fluorescence can identify sentinel (first-draining) lymph nodes during breast cancer surgery. The goggles and ICG signal are used to mark candidate sentinel nodes, and an additional observer may record near-infrared images during the operation for device-performance assessment. These imaging findings do not change the surgical procedure. The candidate nodes and all removed tissue are examined by histopathology, which serves as the reference standard. Two hundred patients undergoing breast cancer surgery will take part. The study measures how well the goggle-based imaging detects nodes that contain cancer, compared with final pathology.
Conditions
- Breast Cancer
- Breast Neoplasms
- Sentinel Lymph Node
- Lymphatic Metastasis
Interventions
AR-ICG near-infrared fluorescence imagingDevice
Augmented-reality goggle-based near-infrared fluorescence imaging with indocyanine green (ICG), used to visualize and mark candidate sentinel lymph nodes during breast cancer surgery. Intraoperative near-infrared imaging may also be recorded by an observer for device-performance assessment. Imaging does not alter surgical management; histopathology serves as the reference standard.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Node-level diagnostic accuracy of AR-ICG fluorescence imaging versus histopathologyTime frame: From surgery to final histopathology (up to ~2 weeks after surgery)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University Clinic for Thoracic and Vascular Surgery, Faculty of Medicine, UKIM
Skopje, North Macedonia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.